AstraZeneca PLC (AZN) on Tuesday said its triple-combination therapy Breztri Aerosphere has been approved by the U.S. Food and Drug Administration for the maintenance treatment of asthma in patients aged 12 years and older.
The therapy is a single inhaler combining an inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) with a long-acting muscarinic antagonist (LAMA).
The approval was based on Phase III KALOS and LOGOS trials, where Breztri (budesonide/glycopyrrolate/formoterol fumarate) showed statistically significant and clinically meaningful improvements in lung function compared with dual-combination ICS/LABA treatments across a broad asthma population.
Breztri was already approved in the U.S. in 2020 for the treatment of adults with chronic obstructive pulmonary disease (COPD).
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.